113 related articles for article (PubMed ID: 15222519)
21. Post-chemotherapy gross tumor volume is predictive of survival in patients with stage III non-small cell lung cancer treated with combined modality therapy.
Stinchcombe TE; Morris DE; Moore DT; Bechtel JH; Halle JS; Mears A; Deschesne K; Rosenman JG; Socinski MA
Lung Cancer; 2006 Apr; 52(1):67-74. PubMed ID: 16499996
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and safety of combination chemotherapy with mitomycin and vinorelbine for the treatment of advanced non-small cell lung cancer.
Wibmer T; Kropf C; Merk T; Schumann C; Hombach V; Krüger S
Lung Cancer; 2008 May; 60(2):231-9. PubMed ID: 18006111
[TBL] [Abstract][Full Text] [Related]
23. Induction chemotherapy with the TIP regimen (paclitaxel/ifosfamide/cisplatin) in stage III non-small cell lung cancer.
Pohl G; Krajnik G; Malayeri R; Müller RM; Klepetko W; Eckersberger F; Schäfer-Prokop C; Pokrajac B; Schmeikal S; Maier A; Ambrosch G; Woltsche M; Minar W; Pirker R
Lung Cancer; 2006 Oct; 54(1):63-7. PubMed ID: 16926060
[TBL] [Abstract][Full Text] [Related]
24. Changes in the natural history of nonsmall cell lung cancer (NSCLC)--comparison of outcomes and characteristics in patients with advanced NSCLC entered in Eastern Cooperative Oncology Group trials before and after 1990.
Wakelee HA; Bernardo P; Johnson DH; Schiller JH
Cancer; 2006 May; 106(10):2208-17. PubMed ID: 16604529
[TBL] [Abstract][Full Text] [Related]
25. Chemotherapy with cisplatin and vinorelbine for elderly patients with locally advanced or metastatic non-small-cell lung cancer (NSCLC).
Pereira JR; Martins SJ; Nikaedo SM; Ikari FK
BMC Cancer; 2004 Sep; 4():69. PubMed ID: 15456520
[TBL] [Abstract][Full Text] [Related]
26. Phase II study of a biweekly regimen of vinorelbine and cisplatin in advanced non-small cell lung cancer.
Chen CH; Lin CM; Kao KC; Chang JW; Tsao TC
Chang Gung Med J; 2007; 30(3):249-55. PubMed ID: 17760276
[TBL] [Abstract][Full Text] [Related]
27. Concurrent cisplatin/etoposide plus 3D-conformal radiotherapy followed by surgery for stage IIB (superior sulcus T3N0)/III non-small cell lung cancer yields a high rate of pathological complete response.
Pourel N; Santelmo N; Naafa N; Serre A; Hilgers W; Mineur L; Molinari N; Reboul F
Eur J Cardiothorac Surg; 2008 May; 33(5):829-36. PubMed ID: 18367406
[TBL] [Abstract][Full Text] [Related]
28. [Comparing cisplatin plus etoposide with combination of mitomycin, ifosfamide and cisplatin in advanced non-small cell lung cancer patients].
Cok G; Göksel T; Soyer S; Atil H; Güzelant A; Aysan T
Tuberk Toraks; 2006; 54(2):161-7. PubMed ID: 16924573
[TBL] [Abstract][Full Text] [Related]
29. [Survival status of stage IV non-small cell lung cancer patients after radiotherapy--a report of 287 cases].
Cai Y; Wang WL; Xu B; Zhu GY; Zhang SW
Ai Zheng; 2006 Nov; 25(11):1419-22. PubMed ID: 17094913
[TBL] [Abstract][Full Text] [Related]
30. Age and comorbidity as independent prognostic factors in the treatment of non small-cell lung cancer: a review of National Cancer Institute of Canada Clinical Trials Group trials.
Asmis TR; Ding K; Seymour L; Shepherd FA; Leighl NB; Winton TL; Whitehead M; Spaans JN; Graham BC; Goss GD;
J Clin Oncol; 2008 Jan; 26(1):54-9. PubMed ID: 18165640
[TBL] [Abstract][Full Text] [Related]
31. Is trimodality approach better then bimodality in stage IIIA, N2 positive non-small cell lung cancer?
Park BB; Park JO; Kim H; Ahn YC; Choi YS; Kim K; Kim J; Shim YM; Ahn JS; Park K
Lung Cancer; 2006 Sep; 53(3):323-30. PubMed ID: 16844258
[TBL] [Abstract][Full Text] [Related]
32. [Activity of toremifene plus mitomycin, vindesin and cisplatin regimen in unresectable non-small cell lung cancer].
Zhou CC; Zhang J; Zheng D; Lu MJ; Lu B; Xu JF
Zhonghua Jie He He Hu Xi Za Zhi; 2004 Aug; 27(8):546-8. PubMed ID: 15388005
[TBL] [Abstract][Full Text] [Related]
33. Survival in untreated early stage non-small cell lung cancer.
Chadha AS; Ganti AK; Sohi JS; Sahmoun AE; Mehdi SA
Anticancer Res; 2005; 25(5):3517-20. PubMed ID: 16101172
[TBL] [Abstract][Full Text] [Related]
34. [Postoperative adjuvant therapy for 189 patients with completely resected non-small cell lung cancer of stage III(A)].
Li Q; Gao JM; Liang PY; Xie FY; Liu GZ
Ai Zheng; 2004 Nov; 23(11 Suppl):1463-6. PubMed ID: 15566658
[TBL] [Abstract][Full Text] [Related]
35. Trimodal therapy for histologically proven N2/3 non-small cell lung cancer: mid-term results and indicators for survival.
Steger V; Walles T; Kosan B; Walker T; Kyriss T; Veit S; Dippon J; Friedel G
Ann Thorac Surg; 2009 Jun; 87(6):1676-83. PubMed ID: 19463576
[TBL] [Abstract][Full Text] [Related]
36. Sex differences in survival in non-small cell lung cancer patients 1974-1998.
Moore R; Doherty D; Chamberlain R; Khuri F
Acta Oncol; 2004; 43(1):57-64. PubMed ID: 15068321
[TBL] [Abstract][Full Text] [Related]
37. [Comparison of screening-detected and symptomatic lung cancer patients].
Nishiwaki Y; Hojo F; Omatsu H; Nagai K
Gan To Kagaku Ryoho; 1998 Aug; 25(10):1486-92. PubMed ID: 9725038
[TBL] [Abstract][Full Text] [Related]
38. [Management of mycobacteriosis in general hospital without isolation ward for tuberculosis patients. Clinical study on pulmonary tuberculosis associated with lung cancer patients].
Watanabe A; Tokue Y; Takahashi H; Sato K; Nukiwa T; Honda Y; Fujimura S
Kekkaku; 1999 Feb; 74(2):157-62. PubMed ID: 10191612
[TBL] [Abstract][Full Text] [Related]
39. Non small cell lung cancer: surgical treatment in the elderly.
Stamatelopoulos A; Kadjianis F; Zoganas L
J BUON; 2009; 14(3):381-9. PubMed ID: 19810127
[TBL] [Abstract][Full Text] [Related]
40. [Non-small cell lung cancer--immunocell BAK (BRM activated killer) therapy].
Ebina T
Nihon Rinsho; 2006 Jul; 64(7):1339-44. PubMed ID: 16838654
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
